Home » Siegall
Category Archives: Siegall
Dr. Clay B. Siegall, Ph.D., is the co-founder of the esteemed Seattle Genetics, Inc. Co-founded in 1997 Dr. Siegall has served as Chief Executive Officer since November 2002 and President since June 2000. Dr. Clay B. Siegall has been in therapeutic drug development and cancer research for nearly 20 years making great advancements in these areas.
Dr. Clay B. Siegall has held a number of different titles since he has been with Seattle Genetics, he held the title of Executive Vice President of Seattle Genetics, Inc., from December 1997 until June 2000. He also served as Chief Scientific Officer from December 1997 until November 2002, Chairman of Seattle Genetics Inc., since March 2004 and interim Chairman of Seattle Genetics Inc., since April 1, 2004.
Dr Clay B. Siegall has served as director for several companies throughout his years in cancer research and therapeutic drug development. Siegall served as director of Mirna Therapeutics, Inc., holding this position since Jan 30, 2013. He was Independent Director of Ultrgenyx pharmaceutical Inc., since Jan 30, 2014.
He has also held the positions of director of Seattle Genetics Inc., since 1997 and Alder Biopharmaceutical Inc. since November 2005. Dr. Siegall has also worked with the Bristol-Myers Squibb Pharmaceutical Research Institute. He was a Senior Research Investigator. He held the title from February 1991 until January 1995. While with Bristol-Myers he was the Principle Scientist from January 1995 to December 1997.
Under Siegall’s leadership Seattle Genetics has had break through success with antibody-based cancer therapies, including ACDETRIS (brentuximab vendotin) approved by the U.S. Food and Drug Administration (FDA) in 2011. Under the leadership of Dr. Siegall Seattle Genetics has secured more than $675 million under public and private financing. This includes the company’s initial public offering in 2001.
Dr. Clay B. Siegall attended the University of Maryland where he received his B.S. in Zoology. He later received his Ph.D. in Genetics from George Washington University. He holds 15 patents and is author of over 70 publications.